Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 286

1.

Strong correlation between the rates of intrinsically antibiotic-resistant species and the rates of acquired resistance in Gram-negative species causing bacteraemia, EU/EEA, 2016.

Jarlier V, Diaz Högberg L, Heuer OE, Campos J, Eckmanns T, Giske CG, Grundmann H, Johnson AP, Kahlmeter G, Monen J, Pantosti A, Rossolini GM, van de Sande-Bruinsma N, Vatopoulos A, Żabicka D, Žemličková H, Monnet DL, Simonsen GS; Ears-Net Participants.

Euro Surveill. 2019 Aug;24(33). doi: 10.2807/1560-7917.ES.2019.24.33.1800538.

2.

Targeting the Mycobacterium ulcerans cytochrome bc1:aa3 for the treatment of Buruli ulcer.

Scherr N, Bieri R, Thomas SS, Chauffour A, Kalia NP, Schneide P, Ruf MT, Lamelas A, Manimekalai MSS, Grüber G, Ishii N, Suzuki K, Tanner M, Moraski GC, Miller MJ, Witschel M, Jarlier V, Pluschke G, Pethe K.

Nat Commun. 2018 Dec 18;9(1):5370. doi: 10.1038/s41467-018-07804-8.

3.

Impact of an Acinetobacter baumannii outbreak on kidney events in a burn unit: A targeted machine learning analysis.

Vauchel T, Pirracchio R, Chaussard M, Lafaurie M, Rouveau M, Rousseau C, Benyamina M, Soussi S, Dépret F, Ferry A, Oueslati H, Chaouat M, Mimoun M, Jarlier V, Moreno N, Mebazaa A, Legrand M.

Am J Infect Control. 2019 Apr;47(4):435-438. doi: 10.1016/j.ajic.2018.09.010. Epub 2018 Nov 29.

PMID:
30503627
4.

Poor Performance of Rapid Molecular Tests to Define Eligibility for the Shortcourse Multidrug-resistant Tuberculosis Regimen.

Guglielmetti L, Sougakoff W, Maitre T, Brossier F, Jarlier V, Robert J, Veziris N, Aubry A; French National Reference Center of Mycobacteria.

Clin Infect Dis. 2019 Apr 8;68(8):1410-1411. doi: 10.1093/cid/ciy808.

PMID:
30239638
5.

Prospective study on antimicrobial resistance in leprosy cases diagnosed in France from 2001 to 2015.

Chauffour A, Lecorche E, Reibel F, Mougari F, Raskine L, Aubry A, Jarlier V, Cambau E; CNR-MyRMA.

Clin Microbiol Infect. 2018 Nov;24(11):1213.e5-1213.e8. doi: 10.1016/j.cmi.2018.06.004. Epub 2018 Jun 12.

PMID:
29906598
6.

Antimicrobial consumption and resistance in adult hospital inpatients in 53 countries: results of an internet-based global point prevalence survey.

Versporten A, Zarb P, Caniaux I, Gros MF, Drapier N, Miller M, Jarlier V, Nathwani D, Goossens H; Global-PPS network.

Lancet Glob Health. 2018 Jun;6(6):e619-e629. doi: 10.1016/S2214-109X(18)30186-4. Epub 2018 Apr 23. Erratum in: Lancet Glob Health. 2018 Sep;6(9):e968.

7.

Interpreting carbapenem susceptibility testing results for Pseudomonas aeruginosa.

Micaëlo M, Brossier F, Bréchot N, Luyt CE, Lu Q, Monsel A, Jarlier V, Aubry A.

Med Mal Infect. 2018 Aug;48(5):365-371. doi: 10.1016/j.medmal.2018.03.003. Epub 2018 Apr 5.

PMID:
29628176
8.

Efficiency of different control measures for preventing carbapenemase-producing enterobacteria and glycopeptide-resistant Enterococcus faecium outbreaks: a 6-year prospective study in a French multihospital institution, January 2010 to December 2015.

Fournier S, Desenfant L, Monteil C, Nion-Huang M, Richard C, Jarlier V; The Ap-Hp Outbreaks Control Group.

Euro Surveill. 2018 Feb;23(8). doi: 10.2807/1560-7917.ES.2018.23.8.17-00078.

9.

Risk factors for extensive drug resistance in multidrug-resistant tuberculosis cases: a case-case study.

Guglielmetti L, Veziris N, Aubry A, Brossier F, Bernard C, Sougakoff W, Jarlier V, Robert J.

Int J Tuberc Lung Dis. 2018 Jan 1;22(1):54-59. doi: 10.5588/ijtld.17.0387.

PMID:
29297426
10.

Neither genotyping nor contact tracing allow correct understanding of multidrug-resistant tuberculosis transmission.

Fournier A, Bernard C, Sougakoff W, Quelet S, Antoun F, Charlois-Ou C, Dormant I, Dufour MO, Hocine N, Jarlier V, Veziris N.

Eur Respir J. 2017 Sep 11;50(3). pii: 1700891. doi: 10.1183/13993003.00891-2017. Print 2017 Sep. No abstract available.

11.

Are moxifloxacin and levofloxacin equally effective to treat XDR tuberculosis?

Maitre T, Petitjean G, Chauffour A, Bernard C, El Helali N, Jarlier V, Reibel F, Chavanet P, Aubry A, Veziris N.

J Antimicrob Chemother. 2017 Aug 1;72(8):2326-2333. doi: 10.1093/jac/dkx150.

PMID:
28535203
12.

Evaluation of the new GenoType NTM-DR kit for the molecular detection of antimicrobial resistance in non-tuberculous mycobacteria.

Mougari F, Loiseau J, Veziris N, Bernard C, Bercot B, Sougakoff W, Jarlier V, Raskine L, Cambau E; French National Reference Center for Mycobacteria.

J Antimicrob Chemother. 2017 Jun 1;72(6):1669-1677. doi: 10.1093/jac/dkx021.

PMID:
28333340
13.

Rapid emergence of Mycobacterium tuberculosis bedaquiline resistance: lessons to avoid repeating past errors.

Veziris N, Bernard C, Guglielmetti L, Le Du D, Marigot-Outtandy D, Jaspard M, Caumes E, Lerat I, Rioux C, Yazdanpanah Y, Tiotiu A, Lemaitre N, Brossier F, Jarlier V, Robert J, Sougakoff W, Aubry A; CNR MyRMA and the Tuberculosis Consilium of the CNR MyRMA; CNR MyRMA and Tuberculosis Consilium of the CNR MyRMA.

Eur Respir J. 2017 Mar 22;49(3). pii: 1601719. doi: 10.1183/13993003.01719-2016. Print 2017 Mar. No abstract available.

14.

Selective reporting of antibiotic susceptibility test results in European countries: an ESCMID cross-sectional survey.

Pulcini C, Tebano G, Mutters NT, Tacconelli E, Cambau E, Kahlmeter G, Jarlier V; EUCIC-ESGAP-EUCAST Selective Reporting Working Group.

Int J Antimicrob Agents. 2017 Feb;49(2):162-166. doi: 10.1016/j.ijantimicag.2016.11.014. Epub 2017 Jan 10.

PMID:
28093208
15.

Estimating the morbidity and mortality associated with infections due to multidrug-resistant bacteria (MDRB), France, 2012.

Colomb-Cotinat M, Lacoste J, Brun-Buisson C, Jarlier V, Coignard B, Vaux S.

Antimicrob Resist Infect Control. 2016 Dec 12;5:56. doi: 10.1186/s13756-016-0154-z. eCollection 2016.

16.

Molecular Investigation of Resistance to Second-Line Injectable Drugs in Multidrug-Resistant Clinical Isolates of Mycobacterium tuberculosis in France.

Brossier F, Pham A, Bernard C, Aubry A, Jarlier V, Veziris N, Sougakoff W; CNR-MyRMA.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e01299-16. doi: 10.1128/AAC.01299-16. Print 2017 Feb.

17.

The in vitro mechanisms of isoniazid and ethionamide resistance poorly reflect those in vivo in Mycobacterium tuberculosis.

Brossier F, Cambau E, Tessier E, Jarlier V, Sougakoff W.

Tuberculosis (Edinb). 2016 Dec;101:144-145. doi: 10.1016/j.tube.2016.09.028. Epub 2016 Sep 29. No abstract available.

PMID:
27865384
18.

Sterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium Ulcerans Infection in Mice.

Chauffour A, Robert J, Veziris N, Aubry A, Jarlier V.

PLoS Negl Trop Dis. 2016 Oct 18;10(10):e0005066. doi: 10.1371/journal.pntd.0005066. eCollection 2016 Oct.

19.

Multidrug and extensively drug-resistant tuberculosis.

Maitre T, Aubry A, Jarlier V, Robert J, Veziris N; CNR-MyRMA.

Med Mal Infect. 2017 Feb;47(1):3-10. doi: 10.1016/j.medmal.2016.07.006. Review.

PMID:
27637852
20.

Comparative study of enzymatic activities of new KatG mutants from low- and high-level isoniazid-resistant clinical isolates of Mycobacterium tuberculosis.

Brossier F, Boudinet M, Jarlier V, Petrella S, Sougakoff W.

Tuberculosis (Edinb). 2016 Sep;100:15-24. doi: 10.1016/j.tube.2016.06.002. Epub 2016 Jun 16.

21.

Quantitative evaluation of extended-spectrum β-lactamase-producing Escherichia coli strains in the wastewater of a French teaching hospital and relation to patient strain.

Drieux L, Haenn S, Moulin L, Jarlier V.

Antimicrob Resist Infect Control. 2016 Mar 29;5:9. doi: 10.1186/s13756-016-0108-5. eCollection 2016.

22.

Photo Quiz: A "Non-Gramable" Strain Isolated from a Cerebrospinal Fluid Sample.

Morel F, Abdennour L, Belaid H, Renvoisé A, Jarlier V, Aubry A.

J Clin Microbiol. 2016 Mar;54(3):511, 823. doi: 10.1128/JCM.00347-14. No abstract available.

23.

XDR-tuberculosis in France: Community transmission due to non-compliance with isolation precautions.

Lafeuille E, Veziris N, Sougakoff W, Roure F, Le Dû D, Dournon N, Caumes E, Jarlier V, Aubry A, Robert J, Bernard C.

Med Mal Infect. 2016 Feb;46(1):52-5. doi: 10.1016/j.medmal.2015.12.008. Epub 2016 Jan 19. No abstract available.

PMID:
26809373
24.

Ongoing increasing temporal and geographical trends of the incidence of extended-spectrum beta-lactamase-producing Enterobacteriaceae infections in France, 2009 to 2013.

Arnaud I, Maugat S, Jarlier V, Astagneau P; National Early Warning, Investigation and Surveillance of Healthcare-Associated Infections Network (RAISIN)/multidrug resistance study group.

Euro Surveill. 2015;20(36). doi: 10.2807/1560-7917.ES.2015.20.36.30014.

25.

Could the DiversiLab® semi-automated repetitive-sequence-based PCR be an acceptable technique for typing isolates of Pseudomonas aeruginosa? An answer from our experience and a review of the literature.

Brossier F, Micaelo M, Luyt CE, Lu Q, Chastre J, Arbelot C, Trouillet JL, Combes A, Rouby JJ, Jarlier V, Aubry A.

Can J Microbiol. 2015 Dec;61(12):903-12. doi: 10.1139/cjm-2015-0372. Epub 2015 Sep 10.

PMID:
26460809
26.

New Insights into the Geographic Distribution of Mycobacterium leprae SNP Genotypes Determined for Isolates from Leprosy Cases Diagnosed in Metropolitan France and French Territories.

Reibel F, Chauffour A, Brossier F, Jarlier V, Cambau E, Aubry A.

PLoS Negl Trop Dis. 2015 Oct 6;9(10):e0004141. doi: 10.1371/journal.pntd.0004141. eCollection 2015.

27.

[European Antibiotic Awareness Day: What is new in France?].

Pulcini C, Alfandari S, Ballereau F, Bonnet E, Bruneel F, Castan B, Chidiac C, Cohen R, Descamps D, Doco-Lecompte T, Gauzit R, Guéry B, Jarlier V, Lesprit P, Marcelin AG, Molina JM, Rabaud C, Riché A, Salmon-Céron D, Senneville E, Stahl JP, Tattevin P, Varon E, Roblot F; conseil d’administration de la SPILF.

Med Mal Infect. 2015 Sep;45(9):345-7. doi: 10.1016/j.medmal.2015.08.001. Epub 2015 Sep 26. French. No abstract available.

PMID:
26411783
28.

Evaluation of excreta management in a large French multi-hospital institution.

Lepainteur M, Nérome S, Bendjelloul G, Monteil C, Cottard-Boulle B, Nion-Huang M, Jarlier V, Fournier S; Network of Infection Control Teams of Assistance Publique – Hôpitaux de Paris.

J Hosp Infect. 2015 Dec;91(4):346-50. doi: 10.1016/j.jhin.2015.07.009. Epub 2015 Aug 15.

PMID:
26386730
29.

Assessing primary and secondary resistance to clarithromycin and amikacin in infections due to Mycobacterium avium complex.

Renvoisé A, Brossier F, Galati E, Veziris N, Sougakoff W, Aubry A, Robert J, Cambau E, Jarlier V, Bernard C.

Antimicrob Agents Chemother. 2015 Nov;59(11):7153-5. doi: 10.1128/AAC.01027-15. Epub 2015 Aug 31. No abstract available.

30.

First multicenter study on multidrug resistant bacteria carriage in Chinese ICUs.

Ma X, Wu Y, Li L, Xu Q, Hu B, Ni Y, Wu A, Sun S, Jarlier V, Robert J.

BMC Infect Dis. 2015 Aug 21;15:358. doi: 10.1186/s12879-015-1105-7.

31.

Characterization of a Clone of Mycobacterium tuberculosis Clinical Isolates with Mutations in KatG (A110V), EthA (Q269STOP), and the inhA Promoter (-15C→T).

Brossier F, Sola C, Bernard C, Jarlier V, Veziris N, Sougakoff W.

J Clin Microbiol. 2015 Sep;53(9):3104. doi: 10.1128/JCM.01537-15. Epub 2015 Jul 8. No abstract available.

32.

Molecular Analysis of the embCAB Locus and embR Gene Involved in Ethambutol Resistance in Clinical Isolates of Mycobacterium tuberculosis in France.

Brossier F, Sougakoff W, Bernard C, Petrou M, Adeyema K, Pham A, Amy de la Breteque D, Vallet M, Jarlier V, Sola C, Veziris N.

Antimicrob Agents Chemother. 2015 Aug;59(8):4800-8. doi: 10.1128/AAC.00150-15. Epub 2015 Jun 1.

33.

French recommendations for the prevention of 'emerging extensively drug-resistant bacteria' (eXDR) cross-transmission.

Lepelletier D, Berthelot P, Lucet JC, Fournier S, Jarlier V, Grandbastien B; National Working Group.

J Hosp Infect. 2015 Jul;90(3):186-95. doi: 10.1016/j.jhin.2015.04.002. Epub 2015 Apr 24. Review.

PMID:
25986165
34.

Spontaneous ascitic fluid infection and bacteremia due to Yersinia pseudotuberculosis in a liver transplant patient.

Renvoisé A, Lemaitre N, Saintenoy G, Benosman H, Geffrier C, Epelboin L, Jarlier V, Poynard T, Thabut D.

Int J Infect Dis. 2015 May;34:122-5. doi: 10.1016/j.ijid.2015.03.019. Epub 2015 Mar 30.

35.

Impact of the BCG vaccination policy on tuberculous meningitis in children under 6 years in metropolitan France between 2000 and 2011.

Van Bui T, Lévy-Bruhl D, Che D, Antoine D, Jarlier V, Robert J.

Euro Surveill. 2015 Mar 19;20(11). pii: 21064.

36.

Helicobacter cinaedi bacteraemia in an HIV-infected patient.

Morel F, Brossier F, Mbadi A, Mégraud F, Jarlier V, Mellon G, Caumes E.

Med Mal Infect. 2015 Jan-Feb;45(1-2):41-3. doi: 10.1016/j.medmal.2014.12.001. Epub 2015 Jan 23. No abstract available.

PMID:
25623629
37.

Detection of OXA-48-like carbapenemase genes by the Xpert® Carba-R test: room for improvement.

Lafeuille E, Laouira S, Sougakoff W, Soulier-Escrihuela O, Leconte J, Garrec H, Tourret J, Jarlier V, Robert J.

Int J Antimicrob Agents. 2015 Apr;45(4):441-2. doi: 10.1016/j.ijantimicag.2014.12.009. Epub 2014 Dec 31. No abstract available.

PMID:
25601530
38.

[Carbapenemase-producing enterobacteriae: epidemiology, strategies to control their spread and issues].

Lepelletier D, Batard E, Berthelot P, Zahar JR, Lucet JC, Fournier S, Jarlier V, Grandbastien B.

Rev Med Interne. 2015 Jul;36(7):474-9. doi: 10.1016/j.revmed.2014.12.006. Epub 2015 Jan 15. Review. French.

PMID:
25600328
39.

Molecular diagnosis of fluoroquinolone resistance in Mycobacterium tuberculosis.

Bernard C, Veziris N, Brossier F, Sougakoff W, Jarlier V, Robert J, Aubry A.

Antimicrob Agents Chemother. 2015 Mar;59(3):1519-24. doi: 10.1128/AAC.04058-14. Epub 2014 Dec 22.

40.

Significant difference in drug susceptibility distribution between Mycobacterium avium and Mycobacterium intracellulare.

Renvoisé A, Bernard C, Veziris N, Galati E, Jarlier V, Robert J.

J Clin Microbiol. 2014 Dec;52(12):4439-40. doi: 10.1128/JCM.02127-14. Epub 2014 Oct 1. No abstract available.

41.

Ruling out false-positive urinary Legionella pneumophila serogroup 1 and Streptococcus pneumoniae antigen test results by heating urine.

Pontoizeau C, Dangers L, Jarlier V, Luyt CE, Guiller E, Fievet MH, Lecsö-Bornet M, Aubry A, Brossier F.

J Clin Microbiol. 2014 Dec;52(12):4347-9. doi: 10.1128/JCM.01916-14. Epub 2014 Sep 24.

43.

Comparing Mycobacterium massiliense and Mycobacterium abscessus lung infections in cystic fibrosis patients.

Roux AL, Catherinot E, Soismier N, Heym B, Bellis G, Lemonnier L, Chiron R, Fauroux B, Le Bourgeois M, Munck A, Pin I, Sermet I, Gutierrez C, Véziris N, Jarlier V, Cambau E, Herrmann JL, Guillemot D, Gaillard JL; OMA group.

J Cyst Fibros. 2015 Jan;14(1):63-9. doi: 10.1016/j.jcf.2014.07.004. Epub 2014 Jul 30.

44.

First Whole-Genome Sequence of a Clinical Isolate of Multidrug-Resistant Mycobacterium bovis BCG.

Renvoisé A, Pang S, Bernard C, Brossier F, Veziris N, Capton E, Jarlier V, Sougakoff W.

Genome Announc. 2014 Jul 10;2(4). pii: e00611-14. doi: 10.1128/genomeA.00611-14.

45.

Long-term control of carbapenemase-producing Enterobacteriaceae at the scale of a large French multihospital institution: a nine-year experience, France, 2004 to 2012.

Fournier S, Monteil C, Lepainteur M, Richard C, Brun-Buisson C, Jarlier V, Ap-Hp Outbreaks Control Group C.

Euro Surveill. 2014 May 15;19(19). pii: 20802.

46.

First evaluation of drug-resistant Mycobacterium tuberculosis clinical isolates from Congo revealed misdetection of fluoroquinolone resistance by line probe assay due to a double substitution T80A-A90G in GyrA.

Aubry A, Sougakoff W, Bodzongo P, Delcroix G, Armand S, Millot G, Jarlier V, Courcol R, Lemaître N.

PLoS One. 2014 Apr 17;9(4):e95083. doi: 10.1371/journal.pone.0095083. eCollection 2014. Erratum in: PLoS One. 2014;9(11):e113219.

47.

Concomitant multidrug-resistant pulmonary tuberculosis and susceptible tuberculous meningitis.

Bernard C, Brossier F, Fréchet-Jachym M, Morand PC, Coignard S, Aslangul E, Aubry A, Jarlier V, Sougakoff W, Veziris N.

Emerg Infect Dis. 2014 Mar;20(3):506-7. doi: 10.3201/eid2003.131205. No abstract available.

48.

Illustration of the difficulty of identifying Streptococcus equi strains at the subspecies level through a case of endocarditis in an immunocompetent man.

Daubié AS, Defrance C, Renvoisé A, Barreda E, D'Alessandro C, Brossier F, Jarlier V, Aubry A.

J Clin Microbiol. 2014 Feb;52(2):688-91. doi: 10.1128/JCM.01447-13. Epub 2013 Nov 20.

49.

Rifampicin mono-resistant tuberculosis in France: a 2005-2010 retrospective cohort analysis.

Meyssonnier V, Bui TV, Veziris N, Jarlier V, Robert J.

BMC Infect Dis. 2014 Jan 10;14:18. doi: 10.1186/1471-2334-14-18.

50.

Multilocus sequence typing scheme for the Mycobacterium abscessus complex.

Macheras E, Konjek J, Roux AL, Thiberge JM, Bastian S, Leão SC, Palaci M, Sivadon-Tardy V, Gutierrez C, Richter E, Rüsch-Gerdes S, Pfyffer GE, Bodmer T, Jarlier V, Cambau E, Brisse S, Caro V, Rastogi N, Gaillard JL, Heym B.

Res Microbiol. 2014 Feb-Mar;165(2):82-90. doi: 10.1016/j.resmic.2013.12.003. Epub 2013 Dec 31.

PMID:
24384536

Supplemental Content

Loading ...
Support Center